(Q40939398)

25 September 2017

title

Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group (English)

1 reference

25 September 2017

1 reference

C Hürny

1 reference

25 September 2017

J Bernhard

1 reference

25 September 2017

A S Coates

1 reference

25 September 2017

M Castiglione-Gertsch

1 reference

25 September 2017

H F Peterson

1 reference

25 September 2017

R D Gelber

1 reference

25 September 2017

J F Forbes

1 reference

25 September 2017

C M Rudenstam

1 reference

25 September 2017

E Simoncini

1 reference

25 September 2017

D Crivellari

1 reference

25 September 2017

A Goldhirsch

1 reference

25 September 2017

H J Senn

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 May 1996

1 reference

25 September 2017

1 reference

inferred from page(s)

published in

The Lancet

1 reference

25 September 2017

volume

347

1 reference

25 September 2017

issue

9011

1 reference

25 September 2017

page(s)

1279-1284

1 reference

Sudden fall in breast cancer death rates in England and Wales

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. The International Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Evaluation of quality of life in patients receiving treatment for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

On the receiving end—II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

On the receiving end--III. Measurement of quality of life during cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation. The International Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Measuring the quality of life of cancer patients: psychometric properties of instruments

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Measuring quality of life in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

A critical appraisal of the quality of quality-of-life measurements

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer--a lesson from the real world--the Swiss Group for Clinical Cancer Research SAKK

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

On the receiving end. IV: Validation of quality of life indicators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Evaluating quality and quantity of life in breast cancer adjuvant trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Psychosocial adjustment in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Influence of physician communication on newly diagnosed breast patients' psychologic adjustment and decision-making

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

Psychosocial correlates of oestrogen and progesterone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990936-8

7 January 2021

10.1016/S0140-6736(96)90936-8

Identifiers

DOI

1 reference

25 September 2017

1 reference